SOURCE: Goldenberg Heller Antognoli & Rowland, P.C.

August 09, 2012 17:27 ET

Goldenberg Heller Antognoli & Rowland, P.C. Welcomes Consolidation of Pending and Future Pradaxa Lawsuits in Southern Illinois

EDWARDSVILLE, IL--(Marketwire - Aug 9, 2012) - Goldenberg Heller Antognoli & Rowland, P.C., a national consumer safety law firm in Edwardsville, Madison County, Illinois -- -- welcomes today's decision by the Judicial Panel on Multidistrict Litigation to transfer and consolidate all pending and future federal lawsuits involving the anticoagulant Pradaxa, In Re: Pradaxa Product Liability Litigation, MDL No. 2385, to the Southern District of Illinois.

Attorney Robert D. Rowland, managing partner of Goldenberg Heller Antognoli & Rowland, P.C.'s mass tort department, explained, "In an order issued August 8, 2012, the JPML assigned the Pradaxa MDL docket No. 2385 to Judge David R. Herndon of the U.S. District Court for the Southern District of Illinois after Plaintiffs filed a petition in May seeking transfer of nearly a dozen Pradaxa personal injury and wrongful death lawsuits, specifically requesting Judge Herndon as transferee judge." 

He went on to note, "Judge Herndon had a distinguished career as a lawyer and judge here in Madison County, Illinois before his appointment to the federal bench. His prior experience generally and with the Yasmine MDL litigation in our federal court makes him an excellent choice by the JPML."

According to Attorney Rowland, "Pradaxa, a direct thrombin inhibitor used to reduce the risk of stroke and embolism in patients with non-valvular atrial fibrillation, was approved by the FDA in October 2010. It is the first anticoagulant to be introduced in the United States in more than 50 years. However," he cautioned, "we believe that Pradaxa causes uncontrolled and excessive bleeding in patients taking the drug and that the manufacturer failed to warn physicians and patients that there is no effective means of reversing Pradaxa's excessive bleeding side effects."

Approximately 275,000 prescriptions were written for Pradaxa between its FDA approval and March 2011. In that time, the agency has received 932 reports of serious adverse events associated with use of the drug. Among the reported events were 120 deaths and 500 reports of severe, life-threatening bleeding. As of Dec. 31, 2011, the FDA received more than 500 reports of U.S. deaths linked to Pradaxa, according to the petition.

For more information about Pradaxa claims, contact Goldenberg Heller Antognoli & Rowland, P.C. at

Contact Information

  • For further information contact:
    Steven Swartz
    McDougall Interactive
    978-750-8000 ext. 18
    Mobile: 978-265-4934
    Email Contact